Similar Items: Metabolic dysfunction–associated steatotic liver disease and cardiovascular disease: Emerging insights into the liver–heart axis
- Global burden of metabolic dysfunction-associated steatotic liver disease attributable to tobacco, 1990–2023, and projected trends to 2038
- Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
- Population attributable fraction of cardiovascular disease, coronary heart disease, and stroke associated with insufficient non-occupational physical activity in Iranian adults: findings from the STEPS 2021 survey
- Effects of alpha-lipoic acid in non-alcoholic fatty liver disease (NAFLD): a systematic review of literature
- Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
- EXPRESSION OF CONCERN: Donor Liver Steatosis: A Risk Factor for Early New‐Onset Diabetes after Liver Transplantation